Verve Therapeutics (VERV) Earnings Date & Reports

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

VERV is expected to report earnings to rise 90.54% to -66 cents per share on August 07

Verve Therapeutics VERV Stock Earnings Reports

Q2'25

Est.

$-0.67

Q1'25

Beat

by $0.30

Q4'24

Beat

by $0.10

Q3'24

Beat

by $0.09

Q2'24

Beat

by $0.09

The last earnings report on May 14 showed earnings per share of -34 cents, beating the estimate of -64 cents. With 300.62K shares outstanding, the current market capitalization sits at 390.45M.

View a ticker or compare two or three

Compare

VERV